Abstract
A recent modeling analysis by Hall attributes the attenuated weight loss observed in patients with type 2 diabetes treated with GLP-1 receptor agonists primarily to reductions in urinary glucose excretion (UGE) and energy expenditure that accompany improved glycemic control. The analysis is conducted entirely within an energy-balance framework. This commentary identifies two elementary but consequential problems. First, glucose excreted in urine is mass leaving the body. Hall’s own equation computes UGE as a mass flux; its subsequent treatment as an “energy sink” is a category error that adds unnecessary assumptions without adding information. Second, the model converts an inferred energy imbalance into an expected mass change via assumed tissue energy densities, and then compares this prediction with observed mass change. Because the energy-to-mass conversion is partly calibrated on the same type of data being predicted, the comparison has limited independent confirmatory power. A mass-balance formulation avoids both problems, supplies a simpler account of the same clinical phenomenon, and generates testable predictions that distinguish the two frameworks.